All In Biotech

NDA 019734 · Chiesi

Cardene In 4.8% Dextrose In Plastic Container

Nicardipine Hydrochloride · Intravenous, Injection

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Jan 30, 1992

Approved uses

1

Original approval plus efficacy supplements

Registered trials

47

10 Phase 3, 4 recruiting

FAERS reports

2,241

2,186 serious, 296 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 13, 2026.

• CARDENE I.V. is a calcium channel blocker indicated for the short-term treatment of hypertension in adults when oral therapy is not feasible. ( 1.1 ) 1.1 Hypertension CARDENE I.V. (nicardipine hydrochloride) is indicated in adults for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits [see Dosage and Administration (2.1) ].

Mechanism: Nicardipine inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. The effects of nicardipine are more selective to vascular smooth muscle than cardiac muscle. In animal models, nicardipine produced relaxation of coronary vascular smooth muscle at drug levels which cause little or no negative inotropic effect.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 30, 1992 Original approval · Type 3 - New Dosage Form
5 products under this application
  • CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER · NICARDIPINE HYDROCHLORIDE 20MG/200ML (0.1MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
  • CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER · NICARDIPINE HYDROCHLORIDE 40MG/200ML (0.2MG/ML) · INJECTABLE, INTRAVENOUS · Discontinued
  • CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER · NICARDIPINE HYDROCHLORIDE 20MG/200ML (0.1MG/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP
  • CARDENE · NICARDIPINE HYDROCHLORIDE 25MG/10ML (2.5MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
  • CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER · NICARDIPINE HYDROCHLORIDE 40MG/200ML (0.2MG/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Nicardipine" as an intervention, any sponsor and status, largest first.

All 47 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • acute kidney injury121
  • hypotension98
  • premature baby98
  • off label use90
  • maternal exposure during pregnancy87
  • foetal exposure during pregnancy74
  • pyrexia71
  • diarrhoea68
  • drug interaction66
  • fall61
  • hyponatraemia59
  • confusional state58

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200422
200515
200696
200796
200857
200974
201050
201146
201286
201328
201421
201539
201633
201762
2018130
201989
202078
2021120
2022239
2023224
2024239
2025261
2026136

Recalls

1 FDA enforcement reports for this application.

  • Aug 6, 2026 · Class II · Ongoing

    CGMP Deviations

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 549 on PubMed

Sponsor: Chiesi · Also marketed as Cardene In 5.0% Dextrose In Plastic Container, Cardene In 0.86% Sodium Chloride In Plastic Container, Cardene, Cardene In 0.83% Sodium Chloride In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.